user-group INVESTOR ACCESS

Venture Capital

MRM Health and IFF Reach Second Milestone in the partnered Type 2 Diabetes program

14 December 2022
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets.

Download

Press Release
Press Release
Download

Related News

BioFirst Group acquires full ownership of Biotrop, cementing its position as a global powerhouse in biologicals
  • Buyout
  • Other news

BioFirst Group acquires full ownership of Biotrop, cementing its position as a global powerhouse in biologicals

arrow-up-right
Mérieux Innovation 2 invests in HighLife Medical, a leading French MedTech company
  • Venture Capital
  • Recent investments & divestments

Mérieux Innovation 2 invests in HighLife Medical, a leading French MedTech company

arrow-up-right
Mérieux Equity Partners announces the first closing of Mérieux Participations 5
  • Buyout
  • Other news

Mérieux Equity Partners announces the first closing of Mérieux Participations 5

arrow-up-right